Analyst consensus rating
Olema Pharmaceuticals Analyst Rating: Strong Buy
OLMA is rated Strong Buy by 10 analysts with a $39.30 target. As of 2026-08-28.
Direct answer
Olema Pharmaceuticals's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $39.30.
Forecast evidence checked August 28, 2026.
Get free Olema Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.79
- Average price target
- $39.30
- High price target
- $59.00
- Low price target
- $20.00
- Low target gap
- +85.4%
- Target upside
- +264.2%
- High target gap
- +446.8%
- Target range width
- 361.4%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 28, 2026
- Valid through
- September 4, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Olema Pharmaceuticals?
Olema Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $39.30.
How far are Olema Pharmaceuticals's low and high targets from the recorded price?
The low target implies +85.4%, while the high target implies +446.8%.
How many analysts are included in Olema Pharmaceuticals's consensus?
The verified consensus includes 10 analysts.
How is Olema Pharmaceuticals's target upside or downside calculated?
The average target of $39.30 is divided by the recorded price of $10.79, then one is subtracted to produce +264.2%. This does not guarantee a future return.
When was Olema Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-28. The dataset is valid through 2026-09-04.